Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J.

JAMA. 2009 Aug 19;302(7):750-7. doi: 10.1001/jama.2009.1201.

PMID:
19690307
2.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

4.

Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.

Šubelj M, Učakar V, Kraigher A, Klavs I.

Euro Surveill. 2016;21(14). doi: 10.2807/1560-7917.ES.2016.21.14.30187.

5.

Adverse events following immunization in Ontario's female school-based HPV program.

Harris T, Williams DM, Fediurek J, Scott T, Deeks SL.

Vaccine. 2014 Feb 19;32(9):1061-6. doi: 10.1016/j.vaccine.2014.01.004. Epub 2014 Jan 15.

PMID:
24440208
6.
7.

Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.

Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, Broder K.

Vaccine. 2015 Jan 15;33(4):519-22. doi: 10.1016/j.vaccine.2014.11.047. Epub 2014 Dec 8.

PMID:
25500173
8.

Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.

Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.

Vaccine. 2015 Apr 15;33(16):1987-92. doi: 10.1016/j.vaccine.2015.01.080. Epub 2015 Feb 9.

PMID:
25678241
9.

Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.

Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, Haber P, Martin D, Broder K.

Clin Infect Dis. 2012 Jun;54(11):1608-14. doi: 10.1093/cid/cis256. Epub 2012 Mar 22.

PMID:
22441652
10.

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.

Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.

PMID:
25258101
11.

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.

Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ.

Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Review.

PMID:
26107345
12.

Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.

Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Singh KP, Bae S.

Hum Vaccin Immunother. 2014;10(1):232-7. doi: 10.4161/hv.26292. Epub 2013 Sep 6.

13.

A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.

Geier DA, Geier MR.

Clin Rheumatol. 2015 Jul;34(7):1225-31. doi: 10.1007/s10067-014-2846-1. Epub 2014 Dec 23.

14.

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Mugo N, Ansah NA, Marino D, Saah A, Garner EI.

Hum Vaccin Immunother. 2015;11(6):1323-30. doi: 10.1080/21645515.2015.1008877.

15.

Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.

Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT.

Vaccine. 2016 May 27;34(25):2841-6. doi: 10.1016/j.vaccine.2016.04.021. Epub 2016 Apr 15.

PMID:
27087150
16.

Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.

Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M.

Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Review.

17.

Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.

Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K.

Vaccine. 2013 Oct 9;31(43):4984-7. doi: 10.1016/j.vaccine.2013.08.001. Epub 2013 Aug 29.

PMID:
23994022
18.

Allergic reactions to Japanese encephalitis vaccine.

Plesner AM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. Review. Erratum in: Immunol Allergy Clin North Am. 2004 May;24(2):335.

PMID:
14753386
19.

U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.

Chang S, O'Connor PM, Slade BA, Woo EJ.

Vaccine. 2013 Feb 27;31(10):1447-52. doi: 10.1016/j.vaccine.2012.10.097. Epub 2012 Nov 8.

PMID:
23142308
20.

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.

Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M.

Pediatr Infect Dis J. 2015 Sep;34(9):992-8. doi: 10.1097/INF.0000000000000773.

PMID:
26090572

Supplemental Content

Support Center